- Home
- HXL vs BBIO Comparison
HXL vs BBIO Comparison
Compare HXL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HXL
- BBIO
- Stock Information
- Founded
- HXL 1946
- BBIO 2015
- Country
- HXL United States
- BBIO United States
- Employees
- HXL N/A
- BBIO N/A
- Industry
- HXL Major Chemicals
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- HXL Industrials
- BBIO Health Care
- Exchange
- HXL Nasdaq
- BBIO Nasdaq
- Market Cap
- HXL 5.3B
- BBIO 5.6B
- IPO Year
- HXL N/A
- BBIO 2019
- Fundamental
- Price
- HXL $62.69
- BBIO $36.85
- Analyst Decision
- HXL Hold
- BBIO Strong Buy
- Analyst Count
- HXL 12
- BBIO 12
- Target Price
- HXL $73.09
- BBIO $52.27
- AVG Volume (30 Days)
- HXL 1.1M
- BBIO 2.7M
- Earning Date
- HXL 01-22-2025
- BBIO 02-20-2025
- Dividend Yield
- HXL 1.07%
- BBIO N/A
- EPS Growth
- HXL 28.23
- BBIO N/A
- EPS
- HXL 1.59
- BBIO N/A
- Revenue
- HXL $1,903,000,000.00
- BBIO $221,902,000.00
- Revenue This Year
- HXL $6.20
- BBIO $2,306.75
- Revenue Next Year
- HXL $9.80
- BBIO N/A
- P/E Ratio
- HXL $40.30
- BBIO N/A
- Revenue Growth
- HXL 6.37
- BBIO 2285.27
- 52 Week Low
- HXL $57.50
- BBIO $21.62
- 52 Week High
- HXL $77.09
- BBIO $39.47
- Technical
- Relative Strength Index (RSI)
- HXL 40.70
- BBIO 63.77
- Support Level
- HXL $63.88
- BBIO $35.36
- Resistance Level
- HXL $67.87
- BBIO $39.47
- Average True Range (ATR)
- HXL 1.65
- BBIO 1.93
- MACD
- HXL -0.29
- BBIO 0.26
- Stochastic Oscillator
- HXL 14.52
- BBIO 70.79
About HXL Hexcel Corporation
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (38% of 2022 sales) and Boeing (25% of prepandemic sales) and their respective subcontractors.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.